Who Actually Qualifies for a GLP-1? The FDA Says One Thing. Insurance Says Another. Telehealth Says Whatever.

Three different rulebooks govern who can get a GLP-1 medication, and they don't agree. The FDA labels set the legal floor. Insurance prior authorization criteria sit on top, often substantially stricter. And telehealth platforms have their own thresholds, frequently more permissive than either. Here's exactly what each one requires — and why the gap matters.

Ask three different sources what the eligibility criteria are for Wegovy or Zepbound, and you'll get three different answers. The FDA-approved labeling specifies one set of thresholds. Most commercial insurance plans require considerably more — higher BMI, multiple comorbidities, often documentation of prior failed weight loss attempts. And many telehealth platforms will write a prescription for patients well below the FDA threshold, sometimes with little more than a self-reported BMI and a credit card.

None of these is necessarily wrong. They're answering different questions. The FDA decides what's safe and effective enough to legally market. Insurance decides what they're willing to pay for. Telehealth decides who they're comfortable prescribing to under their own clinical and legal frameworks. Patients have to navigate all three.

This is a side-by-side breakdown of every layer of GLP-1 eligibility, what each one actually says, and where the real-world frictions show up.

Layer 1: The FDA-Approved Criteria

The FDA labels are the legal floor. They define the populations in which the FDA has determined the benefits of a medication outweigh its risks based on clinical trial data. For chronic weight management indications, both Wegovy and Zepbound use functionally identical FDA criteria.

That's the entirety of the BMI threshold. Two doors in: BMI ≥30 alone, or BMI 27–29.9 with at least one of the listed comorbidities. The list of qualifying comorbidities is intentionally short and practical: high blood pressure, abnormal cholesterol or triglycerides, type 2 diabetes, sleep apnea, or established cardiovascular disease.

What "weight-related comorbid condition" actually means

The FDA list is non-exhaustive ("e.g."), and most clinicians extend it to include other obesity-related conditions: prediabetes, polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease, osteoarthritis with weight-related joint problems, gastroesophageal reflux, and obesity-related infertility. None of these are specifically named in the FDA label, but all are accepted weight-related conditions in clinical practice.

Pediatric criteria

Wegovy was approved in December 2022 for adolescents aged 12 and older, with a separate pediatric BMI threshold: an initial BMI at the 95th percentile or greater standardized for age and sex. Zepbound is not currently approved for pediatric patients. Foundayo (orforglipron, approved April 2026) is also adult-only.

What the FDA does NOT require

The FDA does not require: documentation of prior failed weight loss attempts; participation in a "comprehensive weight management program"; specific lab tests beyond standard medical screening; demonstration of any specific number of comorbidities beyond the threshold of one (for the BMI 27–30 group); ongoing weight loss progress to continue therapy; or any insurance-specific paperwork. Those requirements come from insurance policies, not the FDA.

Layer 2: Insurance Prior Authorization Criteria

This is where the practical eligibility picture for insured patients diverges sharply from the FDA label. Insurance prior authorization (PA) criteria for GLP-1s are typically more restrictive than the FDA threshold, often by a substantial margin. The reasoning is economic: at a list price of $1,000–$1,400 per month, insurers have a strong incentive to limit coverage to the highest-need patients.

Most commercial plans use a tiered approach roughly along these lines:

Beyond BMI, most insurance PA forms also require:

• Documentation of comorbidities at the time of initial prescription. Hypertension, type 2 diabetes, dyslipidemia, OSA, or CVD must be documented in the medical record — usually with ICD-10 codes and supporting lab values or diagnostic reports.
• Enrollment in a comprehensive weight management program. This typically means a documented plan that includes dietary counseling, physical activity recommendations, and behavior modification. Some insurers require formal program participation; others accept a clinician's documentation.
• Documentation of prior failed weight loss attempts. Many plans require evidence that the patient has tried lifestyle modification for 3–6 months without achieving meaningful weight loss before approving GLP-1 therapy.
• Continuation criteria. Most plans require demonstration of meaningful weight loss (often ≥5% of baseline body weight) within 12–16 weeks of starting therapy in order to continue coverage. Plans may also limit total cumulative coverage to a defined number of months or years.
• Step therapy. Some plans require trial of cheaper agents (phentermine, Qsymia, naltrexone-bupropion) before approving GLP-1 therapy.

The specific insurance plan matters more than the FDA label

Two patients with identical clinical profiles can have completely different access depending on what plan they're on. Some plans cover GLP-1s for weight management with relatively standard PA. Some cover them only for diabetes (Ozempic, Mounjaro for T2D) and exclude obesity treatment entirely. Some accept Wegovy as a preferred GLP-1 but exclude Zepbound (this is currently the case with CVS Caremark plans). Medicare Part D historically excluded weight loss medications by statute, with the new GLP-1 Bridge Program scheduled to begin July 2026 carving out a limited exception with its own tiered criteria.

Layer 3: The Telehealth Reality

Telehealth platforms occupy a different position in the eligibility ecosystem. They are constrained by FDA labeling for what they can prescribe, but in practice their thresholds for issuing a prescription are often more permissive than insurance plans — sometimes even more permissive than the FDA label, particularly for compounded GLP-1 medications where the regulatory framework is different.

The variability across telehealth platforms is enormous. A patient with the same clinical profile may be approved on one platform, declined on another, and approved on a third only after producing additional documentation. The factors driving this variability include:

• FDA-approved brand-name vs. compounded. Platforms prescribing brand-name Wegovy or Zepbound generally apply the FDA label criteria as a minimum. Platforms prescribing compounded semaglutide or tirzepatide have historically applied looser criteria — the regulatory framework around 503A compounding pharmacies is different, and the FDA-declared shortages that initially permitted broad compounding access have ended for both drugs (semaglutide in early 2025, tirzepatide in late 2024).
• Clinical intake rigor. Some platforms conduct a meaningful initial consultation with a licensed clinician, screen for contraindications including the boxed warning conditions (MTC, MEN 2), and verify reported BMI through documentation when possible. Others rely largely on patient-reported information and a brief asynchronous review.
• Comorbidity documentation. Some platforms require records from a primary care provider documenting comorbid conditions. Others accept self-attestation.
• State-by-state licensing. Telehealth prescribing is governed state by state. The same platform may be more permissive in some states than others based on local regulatory environment.

Side-by-Side: The Three Layers Compared

The Comorbidity Question: What Actually Counts?

For patients in the BMI 27–30 range, qualifying comorbidities are the difference between yes and no. Here's the practical breakdown of what's commonly accepted:

Quick Reference: Where You Land on Each Layer

To make the eligibility math concrete, here are example scenarios with the FDA, insurance, and telehealth assessment for each:

*Prediabetes is not specifically named in the FDA label as a qualifying comorbidity. Some clinicians treat it as an extension of the dysglycemia/T2D category; others do not.

The Class of People Who Don't Qualify (Yet)

It's worth being explicit about the populations for whom GLP-1 therapy is not appropriate under any of the three rulebooks:

• BMI under 27 without weight-related conditions. The risk-benefit ratio has not been established by the FDA in this population. Telehealth platforms that prescribe to lower-BMI patients with cosmetic weight loss goals are operating outside any of the established frameworks.
• Personal or family history of medullary thyroid carcinoma (MTC). Categorically contraindicated by the boxed warning on every FDA-approved GLP-1.
• Multiple Endocrine Neoplasia type 2 (MEN 2). Same — categorical contraindication.
• Pregnancy. Not approved during pregnancy. Women of reproductive potential are advised to discontinue therapy at least two months before planning to become pregnant due to semaglutide's long half-life.
• History of severe pancreatitis or severe gastroparesis. Not contraindicated absolutely, but generally not initiated; the FDA labels note these populations were excluded from clinical trials.
• Type 1 diabetes. Not indicated; insulin remains the foundation of T1D management.

Detailed coverage of the contraindications and what to discuss with a prescribing clinician is available in our GLP-1 boxed warning explainer.

What This Means in Practice

The three-layer eligibility system creates predictable patterns of access:

If you have insurance that covers GLP-1s for weight management

Your effective gate is your insurance plan's prior authorization criteria, not the FDA label. Pull the PA form for your specific plan, document your comorbidities thoroughly with your primary care clinician, and prepare for the possibility of step therapy or a comprehensive weight management program enrollment. If approved, you'll likely pay $25–$100/month with a manufacturer savings card.

If you have insurance that excludes GLP-1s for weight management

The FDA label is essentially academic for you. Your effective options are: pursuing manufacturer direct programs (LillyDirect at $299–$449/month for Zepbound; NovoCare at $199–$349/month for Wegovy), telehealth platforms prescribing brand-name with discount pricing, or telehealth platforms prescribing compounded GLP-1s at $99–$399/month.

If you have a Type 2 diabetes diagnosis

You have access to a different pathway entirely. Ozempic and Mounjaro are typically covered by both commercial insurance and Medicare Part D for diabetes management, often with substantially lower out-of-pocket costs than the obesity-indicated formulations. The medications are the same molecules; the brand and indication differ.

If you're at the BMI 27–30 borderline

Eligibility hinges entirely on documentable comorbidities. A primary care visit to formally document hypertension, dyslipidemia, prediabetes, or sleep apnea (with appropriate testing) can make the difference between "approved" and "declined" across all three layers.

Where to Go From Here

If you've established that you meet the FDA criteria — or are close enough that your prescribing clinician believes the risk-benefit is favorable — the practical next step is choosing how to access the medication. The right path depends on your insurance situation, your priorities (brand-name vs. compounded, cost vs. clinical oversight), and the specific medication you're seeking.

Affiliate Disclosure: Some provider links on this page are affiliate links. If you sign up through these links, we may receive compensation at no additional cost to you. This does not influence our editorial content, sourcing standards, or eligibility analysis. This article is informational only and does not constitute medical advice. Decisions about whether you qualify for and should start GLP-1 therapy should be made with a licensed clinician.